FibroGen, Inc. (FGEN)

0.35 2.50
Prev Close 14.19
Open 14.31
Day Low/High 14.12 / 14.97
52 Wk Low/High 9.88 / 57.21
Volume 1.35M
Exchange NASDAQ
Shares Outstanding 92.71B
Market Cap 1.25B
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Groovin' With FibroGen

FibroGen's getting jiggy.


Adding to at $12.15 now.

Hotel California

* What's to like? Very little.. * Though the averages have held up (thank you "Nifty Seven"), a look under the hood reveals a dismal picture of broken stocks and charts  "Last thing I remember, I was Running for the door I had to find the passage ba...

Busy Adding to 3 Names

I have added to AdvisorShares Pure US Cannabis ETF , ViacomCBS and FibroGen this morning.    

More on FibroGen

FibroGen appeared in two conferences last week.   To summarize the opportunity in China -- there are currently 700k dialysis patients (this is growing 10% a year).   There are an estimated 120 million Chinese citizens with chronic kidney disease (CK...

More FibroGen Intel to Consider

Biotech is not my area of expertise, so I am trying to throw out as much data as possible on FibroGen in order for subscribers to evaluate the merits of this particular speculative, biotech investment. I don't want to suggest by all the FGEN informa...


Today FibroGen appears at the Jeffries London Healthcare Conference.

Adding to Longs

I added to the following longs this morning: , , , , and . __________  Long C, IVZ, VIAC common and calls, FGEN, MSOS, DISCK. Short C calls, IVZ calls, VIAC puts, FGEN calls, MSOS calls, DISCK calls.

From The Street of Dreams (Part Deux)

Stifel on FibroGen  as the company appeared at the Stifel Healthcare Conference yesterday:  FibroGen Biopharma (FGEN, Hold, $12.58) - CEO Enrique Conterno In the wake of the Roxadustat CRL issuance for CKD anemia in the US, FGEN has refocused on its...

My Rivian Trading Strategy

I have continued to steadily short the shares of Rivian over the last few trading days. I have shorted more RIVN at $177 in premarket trading early this morning.  As stated, my plan has been to start very small and steadily scale into a somewhat lar...


More on FibroGen , here.


Fibrogen presentation, here.

FGEN Weighting

I received several emails from subscribers as to my weighting of a speculative stock like FibroGen .  Give my risk appetite/profile - I am actually quite conservative - I would not likely have more than a 1% percent position in a company with the ch...

FibroGen Update

More positive input, here.

Selling and Adding

I am selling small Boeing , adding to , and I am increasing my overall short exposure.

Is Something Up at FibroGen?

* Where is the $100 million of extra cash coming into the company's coffers from between now and year-end?   As I discussed in my thesis, FibroGen has done a great job of right sizing the company and preserving cash as it finances its drug research ...

More on FibroGen

This morning I am going to deliver a few additional columns on FibroGen - a company I highlighted last week, here.  I want to emphasize that this is a speculative biotech company that should be weighted accordingly. So, just because I am spending mo...


I have a relatively modest sized position in FibroGen . With the shares under $12, I am getting more aggressive in this name. Here was my write up earlier this week.  Remember, this is a speculative position - so size accordingly.

Today's Trades (Before I Go Into a Research Call)

* Added to my short. * Established a trading long rental. * Added to and . * Buying more . * Aggressively adding to cannabis names after Representative Mace announced her legislation will be delivered on Monday, well ahead of expectations. * Added t...

FibroGen Update

* I have begun to add to my holdings based on the company "right sizing" its operations  FibroGen is a very speculative and development stage biotech company.  Its main product is Roxadustat which treats anemia associated with chronic kidney disease...


FibroGen  getting J-I-G-G-Y.


is undergoing a Stage of a Phase 3 Study for Roxadustat for treatment of anemia in patients with lower risk myelodysplastic syndrome - open label, dose selection.  Here is the abstract:  "Anemia is the predominant cytopenia in myelodysplastic syndro...

FibroGen Clinical Program

FibroGen has announced that analyses from the global Phase III Rroxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2021, taking place virtually in the first week of November.


Buying small spec FibroGen  under $11. Not high conviction on timing, though.

Of Note

-  FibroGen  is getting jiggy in a sea of red. -  Not Transitory: Apple and Amazon report further supply chain disruptions. Coming up next?    My candidate is Home Depot . -  With the VIX being contained, and actually down a bit, I suspect we could ...

Adding to FGEN

I added to my small FibroGen holdings but it is a total spec.


gets jiggy this morning. Added small. And I will press my small short on a break below $381.

FibroGen Update

Some good news for FibroGen .  This morning the company announced positive topline results from Whintey, its Phase II clinical study of roxadustat (treatment for anemia).